U.S. patent application number 12/080605 was filed with the patent office on 2008-08-07 for method for producing salts of tolperisone.
This patent application is currently assigned to SANOCHEMIA PHARMAZEUTIKA AG. Invention is credited to Laszlo Czollner, Beate Kalz, Jan Rothenburger, Stefan Welzig.
Application Number | 20080188522 12/080605 |
Document ID | / |
Family ID | 32398619 |
Filed Date | 2008-08-07 |
United States Patent
Application |
20080188522 |
Kind Code |
A1 |
Czollner; Laszlo ; et
al. |
August 7, 2008 |
Method for producing salts of tolperisone
Abstract
The invention relates to a method for producing an acid addition
salt of 2,4'-dimethyl-3-piperidino-propiophenone (tolperisone) with
a pharmaceutically acceptable acid, of the formula (I).
##STR00001## According to the invention, 4-methylpropiophenone is
reacted with piperidine hydrochloride and 1,2-dioxolane in the
presence of an acid serving as a catalyst, and the tolperisone
obtained in the form of an acid addition salt is separated by
filtering after the reaction mixture has cooled down.
Inventors: |
Czollner; Laszlo;
(Ebenfurth, AT) ; Kalz; Beate; (Gartengasse,
AT) ; Rothenburger; Jan; (Bahnstrasse, AT) ;
Welzig; Stefan; (Boerhaavegasse, AT) |
Correspondence
Address: |
ROBINS & PASTERNAK LLP
1731 EMBARCADERO ROAD, SUITE 230
PALO ALTO
CA
94303
US
|
Assignee: |
SANOCHEMIA PHARMAZEUTIKA AG
WIEN
AT
|
Family ID: |
32398619 |
Appl. No.: |
12/080605 |
Filed: |
April 4, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10537434 |
Jul 15, 2005 |
7385060 |
|
|
PCT/AT03/00092 |
Mar 31, 2003 |
|
|
|
12080605 |
|
|
|
|
Current U.S.
Class: |
514/315 |
Current CPC
Class: |
C07D 295/108
20130101 |
Class at
Publication: |
514/315 |
International
Class: |
A61K 31/455 20060101
A61K031/455 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 5, 2002 |
AT |
A 1823/2002 |
Claims
1. Method for manufacturing pharmaceutically acceptable acid
addition salts of 2,4'-dimethyl-3-piperidinopropiophenone
(tolperisone), of formula (A) ##STR00018## said acid addition salts
having a formula (B) ##STR00019## characterized by the fact that
4-methylpropiophenone of the formula ##STR00020## is reacted with
piperidine hydrochloride of the formula ##STR00021## and
1,2-dioxolane of the formula ##STR00022## in presence of an acid
serving as a catalyst, and the tolperisone obtained in the form of
an acid addition salt is separated by filtering after the reaction
mixture has cooled down.
2. Method according to claim 1, characterized by the fact that the
reaction is carried out in the presence of catalytic quantities of
an acid, in particular aqueous hydrochloric acid.
3. Method according to claims 1 or 2, characterized by the fact
that the reaction is carried out in a solvent.
4. Method according to claim 3, characterized by the fact that the
reaction is preferably accomplished in 1,2-dioxolane as a solvent
in a concentration range from 1 to 6 preferably 3.6 mol/lit.
5. Method according to claims 1 to 4, characterized by the fact
that the resulting tolperisone with the inorganic acid, such as
hydrochloric acid is converted, into the addition salt.
6. Method according to claims 1 to 5, characterized by the fact
that tolperisone is isolated as an addition salt by addition to the
reaction mixture of at least a solvent, such as ethyl acetate and
methyl tert-butyl-ether.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation application of U.S.
patent application Ser. No. 10/537,434, filed Jul. 15, 2005, which
is a 371 national stage application of International Application
no. PCT/AT03/00092, filed Mar. 31, 2003, which claims priority to
Austrian Patent Application No. A 1823/2002, filed Dec. 5, 2002,
from which applications priority is claimed pursuant to 35 U.S.C.
.sctn..sctn. 119 and 120, which applications are hereby
incorporated by reference in their entireties.
[0002] The invention relates to a method for manufacturing organic
and inorganic acid addition salts and hydrates of tolperisone
having the general formula B:
##STR00002##
[0003] Tolperisone is the international name for a muscle relaxant
having the chemical name
(RS)-2,4'-Dimethyl-3-piperidinopropiophenone and also having the
molecular formula C.sub.16H.sub.23NO. Tolperisone is a
muscle-relaxing pharmaceutical, with the following formula A
##STR00003##
[0004] The main indications for tolperisone are illnesses which are
accompanied by painful muscle spams, e.g. spinal column syndromes,
muscular pain with degenerative illnesses, sports and occupational
repetitive motion syndromes and the Fibromyalgia syndrome.
[0005] An advantage of the treatment with tolperisone is the fact
that functional parameters e.g. the mobility of the patient, is
also improved. Patients having long-term administration of
tolperisone have a good therapeutic relationship and the confidence
basis necessary for therapeutic success by the absence of central
side effects usually associated with the further employment of this
medicine.
[0006] Tolperisone and its salts with the general formulas A and B
are well-known and can be manufactured by different chemical
pathways. The well-known methods in the synthetic art have the
disadvantage that they utilize raw materials that are not
commercially available, and also have the drawbacks of complicated
reaction conditions on an industrial scale which lead to low
yields.
J. Labelled Cpd. Radiopharm 42, 1125-1134 (1999)
[0007] In order to be able to manufacture radioactively labeled
tolperisone, Ditriech provides a direct synthesis pathway on the
basis of 4'-methylacetophenone and paraformaldehyde. The
multi-level synthesis leads to a mixture of substances and the
tolperisone can only be isolated by column chromatography.
Jap. Pat. 04005283 A2 19920109
##STR00004##
[0008] Disadvantages of this method are the multi-level synthesis,
the intermediate product must be isolated and purified.
Jap. Pat. 54032480 19790309
##STR00005##
[0009] The production of the halogen derivative is complex and
expensive.
Jap. Pat. 54036274 19790316
##STR00006##
[0010] This synthesis pathway starts from expensive raw materials
and it develops several by-products (ie., dibromopentane).
Jap. Pat. 54030178 19790306
##STR00007##
[0011] The raw material needed for this synthetic pathway must be
manufactured over several stages. Furthermore, the reaction must be
worked under exclusion of humidity to avoid the hydrolysis of
aluminum trichloride.
Jap. Pat. 54027571 19790301
##STR00008##
[0012] This synthesis pathway starts from expensive raw materials
and it develops several by-products (e.g. vinyl compounds).
Chem. Pharm. Bull. 42, 1676 (1994):
[0013] Kazuharu et al. describe in Chem. Pharm. Bulletin 42(8) 1676
(1994) the production of tolperisone by the Mannich reaction. The
published yields are relatively high, however several by-products
are removed by aqueous extraction. The multi-level processing is
unfavorable and expensive, since the substance is isolated first in
oily form and only afterwards as the hydrochloride.
RO 75-83082 19750804 (CAN 98: 125629)
##STR00009##
[0015] The use of formaldehyde that is not in protected form has
several disadvantages, like water in the reaction mixture, high
toxicity (IHL-TCLO HMN 17 mg/m.sup.3/30 m; ORL-RAT LD.sub.50 100 mg
kg.sup.-1) or formation of very difficultly soluble
paraformaldehyde.
Jap. Pat. 20,390 (1965)
[0016] Matatsugu et al. published a method for the production of
tolperisone on the basis of paraformaldehyde in a mixture of
nitromethane:ethanol:toluene (40:5, 5:11) using aqueous
hydrochloric acid. The indicated reaction results in a conglomerate
and working with nitromethane is expensive due to its danger.
Hung. Pat. 144,997 (1956)
[0017] Nador et al. describes an industrial method for the
production of tolperisone using ethanol saturated with gaseous
formaldehyde. This method leads to tolperisone hydrochloride, the
yields however are low and working with gaseous formaldehyde is
expensive due to its danger.
[0018] Among the unwanted isomers which are notable in particular
are: [0019] (C):
2-Methyl-1-(3-methylphenyl)-3-piperidin-1-ylpropan-1-one; [0020]
(D): 2-Methyl-1-(2-methyl phenyl)-3-piperidin-1-ylpropan-1-one;
##STR00010##
[0021] On the basis of the synthesis method and the quality
(purity) of the assigned basic materials the following impurities
in the final product (tolperisone) are possible:
TABLE-US-00001 Component Chemical name Chemical Structure
Piperidine HCl Piperidine hydrochloride ##STR00011## C
2-methyl-1-(3-methylphenyl)-3-(1-piperidinyl)-propanonehydrochloride3-to-
lperisone hydrochloride ##STR00012## 4-MMP
1-(4-methylphenyl)-propanone4-methylpropiophenone ##STR00013## E
2-methyl-1-(4-methylphenyl)-propenone ##STR00014## D
2-methyl-1-(2-methylphenyl)-3-(1-piperidinyl)-propanonehydrochloride2-to-
lperisone hydrochloride ##STR00015##
[0022] The objective of the invention is to develop an improved
method for manufacturing tolperisone with improved purity and its
salts, feasible in a technical scale, without the disadvantages
that arise from the well-known synthetic pathways.
[0023] The objective is accomplished with a method, which exhibits
the characteristics of patent claim 1.
[0024] Favourable synthetic arrangements according to the methods
of the invention are the subject of the claims.
[0025] With the below described analytical methods these impurities
can be ascertained to be near 0.1%.
[0026] The analysis methods are described below.
[0027] 1.1. Method 1: Analysis of the Content of Tolperisone and
Impurities 3-tolperisone (C), 4 methylpropiophenone (4-mpp) and
Vinylketone (E):
[0028] The determination of the content of tolperisone and the
impurities mentioned above takes place by means of measurements
against external standards on a HPLC system with UV detection. The
stationary phase consists of a functionalized polysaccharide. As
mobile phase a binary system of a borate buffer and an organic
modifier (acetonitrile) is used.
[0029] 1.2. Method 2: Analysis of the Content 2-Tolperisone
(D):
[0030] For the determination of the content of 2-tolperisone a HPLC
system along with UV detection is likewise used. The stationary
phase is a calixarene bound on silicate. As mobile phase a mixture
of phosphate buffer and methanol is used.
[0031] 1.3. Method 3: Analysis of the Content of Piperidine
Hydrochloride:
[0032] For the regulation of piperidine HCl a quantitative LC/MS
method is used. The stationary phase consists of octadecysilyl
derivatized silica gel. The binary mobile phase contains tri-chloro
acetic acid and methanol.
[0033] With the described methods also the levels of C and D can be
ascertained (determined), although these position isomers hardly
differ in their chemical characteristics from tolperisone and
therefore are separated with difficulty.
[0034] So far for determining the content of tolperisone a regular
titrimetric method was used (Pharm. Jap. XI), with which only the
sum of the levels B, C and D can be determined.
[0035] With the new HPLC method for determining tolperisone,
2-tolperisone, 3-tolperisone and the remaining impurities and the
LC/MS method for determining piperidine hydrochloride, the problems
of the well-known analyses are eliminated.
[0036] With these analysis methods, the purity was determined
according to the invention for the tolperisone made according to
the invention and for tolperisone preparations available in the
marketplace.
[0037] The results are summarized in the following table:
TABLE-US-00002 Product description 2-Tolperisone 3-Tolperisone
Piperidine Vinyl Ketone 4-MPP Mydeton 50 mg 0.3% 0.8% <0.05%
<0.05% <0.05% Tablets from Gedeon Richter Mydeton 510 mg 0.6%
1.2% <0.05% <0.05% <0.05% Tablets from Gedeon Richter
Mydocalm 50 mg 0.6% 1.1% <0.05% <0.05% <0.05% Tablets From
Strathmann Toperisone of the <0.05% 0.1% <0.05% <0.05%
<0.05% present invention
[0038] The analyses summarized in the table show the fact that
tolperisone is clearly worse in products present in the market in
its purity profile, particularly in the content of position
isomers, than the tolperisone available in accordance with the
invention and thus does not correspond to the current guidelines of
the European regulatory agencies.
[0039] The method according to invention for the synthesis of
tolperisone can be shown as follows:
##STR00016##
[0040] As the starting materials 4-methylpropiophenone, piperidine
hydrochloride and 1,2-dioxolane are used as reaction partners and
the latter is used preferentially also as solvent.
[0041] Using 1,2-dioxolane in place of formaldehyde and the high
yield achieved after the direct isolation of tolperisone makes the
single-step reaction economical also on an industrial scale.
[0042] With the method according to the invention it is feasible
that the starting 4-methylpropiophenone may be contaminated with up
to 5% 3-methylpropiophenone and up to 2% 2-methylpropiophenone, and
with the methods according to the invention nevertheless the
necessary final product purity is attained.
[0043] With the method according to the invention for manufacturing
salts of tolperisone of the formula B aqueous hydrochloric acid can
be used in catalytic quantities for the aminomethylation reaction
accomplished in 1,2-dioxolane. Thus the final product of the salts
of tolperisone can be separated easily by the addition of ethyl
acetate and tert-butyl methylether in accordance with general
formula B for example as chloride (X.dbd.Cl) and can be separated
from the reaction mixture by precipitation.
[0044] The separated salt of tolperisone possesses already high
purity and a favorable impurity profile, however if necessary it
can be further purified e.g. by further recrystallization.
[0045] Altogether the method of the invention is suitable also for
carrying out on an industrial scale, since a purification step
represents a small expenditure by means of salt precipitation only.
The method of the invention can be implemented and also
automated.
[0046] The method of the invention permits manufacturing of
suitable salts of tolperisone with acids by addition of the
pharmaceutical active, to preferential acids such as mineral acids,
and more in particular hydrochloric acid.
[0047] Favourable method and variants thereof according to the
invention are described on the basis the following examples:
EXAMPLE 1
Production of Tolperisone Hydrochloride
[0048] In a 3-L-three neck flask with a reflux condenser, a calcium
chloride drying tower, and under an argon flow, 200 ml of
1,3-dioxolane and 146.2 ml of 4-methylpropiophenone are subjected
to agitation and then there is added through a funnel 100 g
piperidine hydrochloride and 4.0 ml of 33% aqueous hydrochloric
acid. The powder in the funnel is washed afterwards with 20 ml
1,3-dioxolane, and the stirrer is switched on in the reaction
flask. The reaction mixture is purged once with argon and stirred
at 100-105.degree. C. bath temperature (83-86.degree. C. interior
temperature). The white precipitate dissolves after approximately
15-16 hours. After 18-20 hours the thin layer chromatogram shows no
more piperidine. After 24 hours the heating is switched off and the
oil bath is removed and while still warm, and under vigorous
stirring to the clear reaction solution, there is added 800 ml
ethyl acetate and then the solution is cooled to ambient
temperature and then further treated with 400 ml methyl
tert-butylether (MTBE). The resulting precipitate is agitated at 0
to 10.degree. C. for an additional 2 hours, and then filtered off
over a glass filter (Po-3) and washed afterwards twice with 200 ml
MTBE each time. The substance is dried in the vacuum drying oven at
75-80.degree. C. and 20-40 mbar for 16 to 24 hours.
[0049] Yield: 206.5 g (89.1%, computed on piperidine hydrochloride)
colorless powder
[0050] mp.: 169.degree. C.
[0051] Analysis:
TABLE-US-00003 Melting point 2-Tolperisone 3-Tolperisone
4-Tolperisone Piperidine Other Impurities 4-MPP 169.degree. C.
0.22% 0.30% 98.0% <0.05% <0.05% <0.05%
EXAMPLE 2
Purification of Tolperisone Hydrochloride
[0052] Into a 500 ml-three-necked flask with stirrer, reflux
condenser and dropping funnel 58.0 g tolperisone are added and
mixed with 87 ml of isopropyl alcohol. The reaction mixture is
heated up to the boiling point, whereby a clear solution develops.
The warm reaction solution is mixed with 261 ml MTBE and cooled
under constant stirring to ambient temperature. The resulting
suspension is cooled under stirring conditions at ambient
temperature for 14-18 hours, then further cooled to 5-10.degree. C.
and after 2-3 hours of stirring it is filtered off. The precipitate
is washed afterwards twice with 80 ml MTBE each and dried in the
vacuum oven at 55-60.degree. C. and 30-50 mbar for 14 to 24
hours.
[0053] Yield: 48.0 g (82.9%) colorless substance
[0054] Smp.: 171.degree. C.
[0055] analysis:
TABLE-US-00004 Melting point 2-Tolperisone 3-Tolperisone
4-Tolperisone Piperidine Other Impurities 4-MPP 171.degree. C.
<0.05% 0.16% 98.9% <0.05% <0.05% <0.05%
EXAMPLE 3
Industrial Production of Tolperisone Hydrochloride
[0056] 75 kg piperidine hydrochloride and 105 kg
4-methylpropiophenone are heated to 90.degree. C. with 180 kg of
1,3-dioxolane and 12 kg of hydrochloric acid under a nitrogen
atmosphere for 7 to 20 hours. With addition of 500 kg of ethyl
acetate and 440 kg MTBE at a temperature in the range of
(40-80.degree. C.), a suspension of the product is produced. After
that the solid is separated from the liquid as a damp product and
then dried at 60-80.degree. C. in the vacuum oven (200-500 mbar)
over a period of 12-24 hours whereby 140 kg (81.5%) of colorless
crystals are isolated.
[0057] MP: 170.degree. C.
[0058] Analysis:
TABLE-US-00005 Melting point 2-Tolperisone 3-Tolperisone
4-Tolperisone Piperidine Other Impurities 4-MPP 170.degree. C.
0.47% 0.36% 97.8% 0.9% <0.05% <0.05%
EXAMPLE 4
Industrial Recrystallization of Tolperisone Hydrochloride
[0059] 60 kg of tolperisone (from example 3) are heated up in 410
kg of 2-Butanone and 71 kg of isopropanol under nitrogen atmosphere
and under reflux. After an optional hot filtration, by cooling a
suspension of the product results. After that the solid is
separated from the liquid as a damp product and then dried at
60-80.degree. C. in the vacuum oven (200-500 mbar) over a period of
12-24 hours whereby 45 kg (75%) of colorless crystals are
isolated.
[0060] mp.: 173.degree. C.
[0061] Analysis:
TABLE-US-00006 Melting point 2-Tolperisone 3-Tolperisone
4-Tolperisone Piperidine Other Impurities 4-MPP 173.degree. C.
<0.05% 0.14% 98.5% <0.05% <0.05% <0.05%
EXAMPLE 5
Industrial Production of Tolperisone Hydrochloride
[0062] 107 kg of piperidine hydrochloride and 150 kg of
4-methylpropionphenone are heated up to 90.degree. C. with 159 kg
of 1,3-dioxolane and 107 L of hydrochloric acid under a nitrogen
atmosphere for 7 to 20 hours. With addition of 783 kg ethyl acetate
and 322 kg of methyl tert-butylether at a temperature of
(40-80.degree. C.), a suspension of the product is produced. After
separating the liquid, the damp product is dried at 60-80.degree.
C. in the vacuum oven (200-500 mbar) for a period of 12-24 hours,
whereby 200 kg (81.5%) colorless crystals are isolated.
[0063] mp.: 170.degree. C.
EXAMPLE 6
Industrial Recrystallization of Tolperisone Hydrochloride
[0064] 190 kg of tolperisone (from example 5) in 1300 kg of
2-butanone and 224 kg isopropanol are heated under nitrogen
atmosphere and refluxed. After an optimal hot filtration, by
cooling a suspension of the product is produced. After separating
the liquid, the damp product is dried at 60-80.degree. C. in the
vacuum oven (200-500 mbar) for a period of 12-24 hours, whereby 143
kg (75%) colorless crystals are isolated.
[0065] mp.: 173.degree. C.
[0066] In summary, an example of the invention can be represented
as follows:
[0067] A method is described for manufacturing an acid addition
salt of 2,4'-dimethyl-3-piperidinopropiophenone (tolperisone) with
a pharmaceutical acceptable acid, of the formula
##STR00017##
by reacting 4-methylpropiophenone with piperidine hydrochloride and
1,2-dioxolane in the presence of an acid as catalyst and the
resulting tolperisone as an acid addition salt is filtered off
after cooling of the reaction mixture.
* * * * *